Zoetis Inc. (NYSE:ZTS) Shares Bought by NorthRock Partners LLC

NorthRock Partners LLC lifted its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 57.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,520 shares of the company's stock after buying an additional 2,009 shares during the quarter. NorthRock Partners LLC's holdings in Zoetis were worth $899,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Atlantic Edge Private Wealth Management LLC grew its holdings in Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 140 shares during the period. Rakuten Securities Inc. boosted its holdings in shares of Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 166 shares during the last quarter. Navigoe LLC purchased a new stake in shares of Zoetis during the 4th quarter valued at $30,000. Murphy & Mullick Capital Management Corp purchased a new stake in shares of Zoetis during the 4th quarter valued at $44,000. Finally, Asset Planning Inc acquired a new stake in shares of Zoetis during the 4th quarter worth $58,000. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Up 3.4%

NYSE ZTS opened at $160.26 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The business has a 50 day moving average price of $156.49 and a two-hundred day moving average price of $165.56. The stock has a market cap of $71.35 billion, a PE ratio of 29.30, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.38 earnings per share. As a group, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Piper Sandler lifted their target price on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Monday. StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Morgan Stanley dropped their target price on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. UBS Group cut their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Finally, Barclays boosted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Zoetis currently has an average rating of "Buy" and a consensus price target of $212.75.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. The trade was a 2.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.